HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LONGBIO-B

120.500

+2.6002.21%

Volume:130.53K

Turnover:15.77M

Market Cap:9.20B

PE:-38.87

High:124.800

Open:122.000

Low:115.600

Close:117.900

52wk High:165.900

52wk Low:72.650

Shares:76.32M

HK Float Shares:75.06M

Volume Ratio:2.25

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.100

ROE:--

ROA:-54.56%

PB:6.99

PE(LYR):-38.87

PS:3125.20

Loading ...

Overview Company News Filings

LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise

Bulletin Express

LONGBIO-B Issues 2.12895 Million Shares Following Full Exercise of Over-Allotment Option

LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO

Bulletin Express

LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06

Bulletin Express

Longbio-B Concludes Share Price Stabilization Period and Related Actions

Longbio Pharma Says IPO Stabilization Period Ends After Full 2,128,950-share Greenshoe Exercise at HK$ 96.06

LongBio Pharma Nets HK$194 Million From Full Exercise of Hong Kong IPO Overallotment Option

MT Newswires Live

LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates

Bulletin Express

LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds

Bulletin Express

LONGBIO-B Fully Exercises Over-Allotment Option

Longbio-B Surges Over 6% as Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint

LongBio Pharma (Suzhou) (SEHK:1779) Stock Valuation Looks Stretched After Recent Gain And High P/B Ratio

Simply Wall St.

LongBio Pharma's Seasonal Allergy Drug LP-003 Meets Main Goal of Study

MT Newswires Live

LongBio Pharma’s LP-003 Hits Primary Goals in China Phase III Seasonal Allergic Rhinitis Study

Bulletin Express

LONGBIO-B's Phase III Trial for Seasonal Allergic Rhinitis Drug LP-003 Meets Primary Endpoint

Longbio Pharma (Suzhou) Co - Phase Iii Trial of Lp-3 for Seasonal Allergic Rhinitis Meets Primary Endpoints

THOMSON REUTERS

LongBio Pharma Announces 2025 AGM; Shareholders to Vote on Profit Distribution, Auditor Re-appointment and Dual Mandates

Bulletin Express

Can LONGBIO-B Maintain Its Lofty Valuation Ahead of a Potential Stock Connect Inclusion?

Movement Alert｜Tiachen Bio-B Rises 6.37% in Regular Trading, Sustaining IPO Oversubscription Momentum on Second Trading Day

Regulator Seeks Clarification from Weizhao Semiconductor on Pricing Disparities Ahead of Planned Hong Kong IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/01779/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"01779","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01779\",,,,,undefined,":{"symbol":"01779","market":"HK","secType":"STK","nameCN":"LONGBIO-B","latestPrice":120.5,"timestamp":1787645292869,"preClose":117.9,"halted":0,"volume":130530,"delay":0,"changeRate":0.022052586938083072,"floatShares":75059200,"shares":76322100,"eps":-3.099834,"marketStatus":"Not Yet Opened","change":2.6,"latestTime":"08-25 16:08:12","open":122,"high":124.8,"low":115.6,"amount":15765528,"amplitude":0.078032,"askPrice":120.5,"askSize":4700,"bidPrice":119.6,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.261,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":0,"adr":0,"listingDate":1780588800000,"exchange":"SEHK","adjPreClose":117.9,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"volumeRatio":2.2521325659888234,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01779\",,,,,undefined,":{"symbol":"01779","floatShares":75059200,"roa":"-54.56%","roe":"--","lyrEps":-3.099834,"volumeRatio":2.2521325659888234,"shares":76322100,"dividePrice":0,"high":124.8,"amplitude":0.078032,"preClose":117.9,"low":115.6,"week52Low":72.65,"pbRate":"6.99","psRate":"3125.20","week52High":165.9,"institutionHeld":0,"latestPrice":120.5,"committee":-0.958333,"eps":-3.099834,"divideRate":0,"volume":130530,"delay":0,"ttmEps":-3.261,"open":122,"prevYearClose":96.06,"prevWeekClose":114.9,"prevMonthClose":96.35,"prevQuarterClose":150.9,"fiveDayClose":114.7,"twentyDayClose":97.1,"sixtyDayClose":96.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01779\",params:#limit:5,,,undefined,":[{"date":"2026-08-21","symbol":"01779","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787275800000,"name":null,"time":"","dateTimestamp":1787241600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01779\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01779\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1784563200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01779\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01779","date":"2026-08-24","current":-36.951855,"percent":0.423077,"low":-57.574283,"twenty":-51.868443,"median":-41.09187,"eighty":-32.927661,"high":-30.168259,"avg":-42.059048,"sd":8.48357,"marketCap":8747372385},"quantilePoints":[{"date":"2026-06-12","current":-52.571631,"twenty":-51.987096,"median":-51.066007,"eighty":-49.243383,"marketCap":10676394285},{"date":"2026-06-18","current":-52.044895,"twenty":-52.077848,"median":-51.840962,"eighty":-50.705966,"marketCap":10594781820},{"date":"2026-06-26","current":-54.937294,"twenty":-55.921485,"median":-52.086085,"eighty":-51.049188,"marketCap":11128972500},{"date":"2026-07-03","current":-38.82993,"twenty":-55.511514,"median":-52.086085,"eighty":-50.54697,"marketCap":7871893215},{"date":"2026-07-10","current":-35.616464,"twenty":-55.275063,"median":-51.840962,"eighty":-39.024704,"marketCap":7211574180},{"date":"2026-07-17","current":-31.236455,"twenty":-55.113833,"median":-50.626468,"eighty":-33.702374,"marketCap":6347223982},{"date":"2026-07-24","current":-32.543593,"twenty":-53.991029,"median":-39.576969,"eighty":-32.682309,"marketCap":6614319322},{"date":"2026-07-31","current":-35.105215,"twenty":-52.48276,"median":-38.82993,"eighty":-32.450461,"marketCap":7148510002},{"date":"2026-08-07","current":-41.09187,"twenty":-52.1108,"median":-38.793333,"eighty":-32.612951,"marketCap":8383825950},{"date":"2026-08-14","current":-43.58221,"twenty":-52.013269,"median":-39.316865,"eighty":-32.896956,"marketCap":8903178000},{"date":"2026-08-21","current":-41.637947,"twenty":-51.877603,"median":-40.334419,"eighty":-32.925453,"marketCap":8524792935},{"date":"2026-08-24","current":-42.740486,"twenty":-51.868443,"median":-41.09187,"eighty":-32.927661,"marketCap":8747372385}],"updateTime":1787681148827},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01779\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1130187592","title":"LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1130187592","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130187592?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:24","pubTimestamp":1783337071,"startTime":"0","endTime":"0","summary":"LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133494330","title":"LONGBIO-B Issues 2.12895 Million Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1133494330","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133494330?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:22","pubTimestamp":1783336935,"startTime":"0","endTime":"0","summary":"LONGBIO-B (01779) has announced the issuance and allotment of 2.12895 million H shares.This share issuance is a result of the full exercise of an over-allotment option, which was completed on July 6, 2026.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196851211","title":"LongBio Pharma Posts Stable Share Base in First HKEX Monthly Return Post-IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1196851211","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196851211?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:07","pubTimestamp":1783336036,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) filed its inaugural Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 June 2026, covering activity from its Main Board...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189095400","title":"LongBio Ends Stabilization; Over-Allotment Option Fully Exercised for 2.13 Million H Shares at HK$96.06","url":"https://stock-news.laohu8.com/highlight/detail?id=1189095400","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189095400?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:45","pubTimestamp":1782989108,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. (LONGBIO-B) announced the completion of the 30-day post-listing stabilization period for its Global Offering, which concluded on 2 July 2026. During this window,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176724510","title":"Longbio-B Concludes Share Price Stabilization Period and Related Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=1176724510","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176724510?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:44","pubTimestamp":1782989079,"startTime":"0","endTime":"0","summary":"Longbio-B (SEHK: 01779) has announced the conclusion of the share price stabilization period for its global offering.The stabilization period ended on Thursday, July 2, 2026, which marks 30 days...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648501661","title":"Longbio Pharma Says IPO Stabilization Period Ends After Full 2,128,950-share Greenshoe Exercise at HK$ 96.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2648501661","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648501661?lang=en_us&edition=fundamental","pubTime":"2026-07-02 18:40","pubTimestamp":1782988842,"startTime":"0","endTime":"0","summary":"LongBio Pharma says IPO stabilization period ends after full 2,128,950-share greenshoe exercise at HK$ 96.06LongBio Pharma’s IPO stabilization period ended July 2, 2026, 30 days after the Hong Kong pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL7Nbn8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648591623","title":"LongBio Pharma Nets HK$194 Million From Full Exercise of Hong Kong IPO Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2648591623","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648591623?lang=en_us&edition=fundamental","pubTime":"2026-07-01 11:06","pubTimestamp":1782875180,"startTime":"0","endTime":"0","summary":"LongBio Pharma   said the overallotment option of its Hong Kong initial public offering was fully exercised on Tuesday, according to a same-day Hong Kong bourse filing.The biopharmaceutical company expects to receive additional net proceeds of about HK$194.3 million.The exercise involved the issue of 2.13 million additional H-shares at HK$96.06 each, representing about 15% of the total offer shares available under the global offering.Dealings in the overallotment shares are expected to begin on July 6, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPOS","BK1161","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173293167","title":"LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1173293167","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173293167?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:44","pubTimestamp":1782830681,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126218520","title":"LongBio Pharma Fully Exercises 15% Over-Allotment Option, Secures HK$194.30 Million in Additional Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1126218520","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126218520?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:42","pubTimestamp":1782830577,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. announced the complete exercise of the 15% over-allotment option linked to its recent global offering, resulting in the issuance of 2.13 million additional H shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123698768","title":"LONGBIO-B Fully Exercises Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1123698768","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123698768?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:32","pubTimestamp":1782829939,"startTime":"0","endTime":"0","summary":"The company has announced that the sole sponsor and overall coordinator, acting on behalf of the international underwriters, has fully exercised the over-allotment option as detailed in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130468719","title":"Longbio-B Surges Over 6% as Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1130468719","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130468719?lang=en_us&edition=fundamental","pubTime":"2026-06-30 11:08","pubTimestamp":1782788904,"startTime":"0","endTime":"0","summary":"Shares of LONGBIO-B (01779) have risen more than 6%. At the time of writing, the stock is up 6.56% to HK$161, with a trading turnover of HK$22.92 million.The move follows a recent company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","01779","VXUS","III","BK4134","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642265502","title":"LongBio Pharma (Suzhou) (SEHK:1779) Stock Valuation Looks Stretched After Recent Gain And High P/B Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2642265502","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642265502?lang=en_us&edition=fundamental","pubTime":"2026-06-12 13:25","pubTimestamp":1781241940,"startTime":"0","endTime":"0","summary":"Event overview and immediate market reaction\nLongBio Pharma (Suzhou) (SEHK:1779) moved higher in the latest session, with the stock closing at HK$141.9 after a 3.2% gain for the day, drawing fresh attention from biotech focused investors.\nSee our latest analysis for LongBio Pharma (Suzhou).\nThe 3.2% one day share price return fits into a year to date share price return of 7.66%. This suggests momentum has been gradually building as investors reassess LongBio Pharma (Suzhou)'s risk and growth...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1779/longbio-pharma-suzhou-shares/news/longbio-pharma-suzhou-sehk1779-stock-valuation-looks-stretch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1779/longbio-pharma-suzhou-shares/news/longbio-pharma-suzhou-sehk1779-stock-valuation-looks-stretch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642256141","title":"LongBio Pharma's Seasonal Allergy Drug LP-003 Meets Main Goal of Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2642256141","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642256141?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:40","pubTimestamp":1781232040,"startTime":"0","endTime":"0","summary":"LongBio Pharma's  seasonal allergic rhinitis treatment LP-003 met the main goal of a phase 3 study, the firm said in a Hong Kong bourse filing Friday.According to LongBio, the late-stage study in China met its pre-specified primary endpoints with \"highly statistically and clinically significant\" results.The firm enrolled 546 patients in the study, including those who did not achieve satisfactory results with standard treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118631830","title":"LongBio Pharma’s LP-003 Hits Primary Goals in China Phase III Seasonal Allergic Rhinitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1118631830","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118631830?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:20","pubTimestamp":1781216447,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. reported that its lead candidate LP-003 met all pre-specified primary endpoints in a China-based Phase III clinical trial targeting moderate-to-severe seasonal...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100372939","title":"LONGBIO-B's Phase III Trial for Seasonal Allergic Rhinitis Drug LP-003 Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=1100372939","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100372939?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:20","pubTimestamp":1781216427,"startTime":"0","endTime":"0","summary":"LONGBIO-B (HKEX: 01779) has announced that the Phase III clinical trial for LP-003, targeting seasonal allergic rhinitis (hay fever), has successfully achieved its pre-defined primary endpoint. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237367","title":"Longbio Pharma (Suzhou) Co - Phase Iii Trial of Lp-3 for Seasonal Allergic Rhinitis Meets Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642237367?lang=en_us&edition=fundamental","pubTime":"2026-06-12 06:12","pubTimestamp":1781215949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167380443","title":"LongBio Pharma Announces 2025 AGM; Shareholders to Vote on Profit Distribution, Auditor Re-appointment and Dual Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1167380443","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167380443?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:43","pubTimestamp":1781016201,"startTime":"0","endTime":"0","summary":"LongBio Pharma (Suzhou) Co., Ltd. has issued a notice convening its 2025 Annual General Meeting (AGM) for 4:00 p.m. on 30 June 2026 at the company’s headquarters (5th Floor, Building F, Area A, No....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190963931","title":"Can LONGBIO-B Maintain Its Lofty Valuation Ahead of a Potential Stock Connect Inclusion?","url":"https://stock-news.laohu8.com/highlight/detail?id=1190963931","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190963931?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:37","pubTimestamp":1781005044,"startTime":"0","endTime":"0","summary":"The Hang Seng Healthcare Index has been in a downtrend for nearly 40 trading sessions since April 17, with a cumulative decline of approximately 25% as of June 8. The recent string of negative...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165094910","title":"Movement Alert｜Tiachen Bio-B Rises 6.37% in Regular Trading, Sustaining IPO Oversubscription Momentum on Second Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=1165094910","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165094910?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:33","pubTimestamp":1780968836,"startTime":"0","endTime":"0","summary":"On June 9, Tiachen Bio-B rose 6.37% in regular trading, trading at 145.1 HKD/share, with trading volume of 17.38 million HKD. The stock has accumulated a premium of approximately 51% over its IPO...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159755444","title":"Regulator Seeks Clarification from Weizhao Semiconductor on Pricing Disparities Ahead of Planned Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1159755444","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159755444?lang=en_us&edition=fundamental","pubTime":"2026-06-05 22:22","pubTimestamp":1780669361,"startTime":"0","endTime":"0","summary":"On June 5th, China's securities regulator issued a series of requests for supplementary information to companies seeking overseas listings. The international department of the China Securities...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01779"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}]}}